Foghorn Therapeutics
FHTX
87 hedge funds and large institutions have $190M invested in Foghorn Therapeutics in 2024 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 12 reducing their positions, and 8 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 12
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
10% more funds holding
Funds holding: 79 → 87 (+8)
0.12% more ownership
Funds ownership: 72.29% → 72.41% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
49% less capital invested
Capital invested by funds: $372M → $190M (-$182M)
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.71M |
| 2 |
DM
Deerfield Management
New York
|
+$1.66M |
| 3 |
BlackRock
New York
|
+$1.59M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.09M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$688K |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.69M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$756K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$182K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$173K |
| 5 |
Jane Street
New York
|
-$173K |
FHTX Hedge Fund Activity: Q4 2024 in Review
87 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q4 2024, worth a combined $190M — down 49% from $372M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new FHTX positions and 8 closed out — a net gain of 9 holders — while 32 added to existing stakes and 12 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $1.71M. The largest seller was Fidelity Investments, cutting an estimated $4.69M.
- 87 institutional investors held Foghorn Therapeutics (FHTX) as of Q4 2024, up from 79 in Q3 2024.
- Funds reported $190M of Foghorn Therapeutics stock for Q4 2024, down 49% quarter-over-quarter.
- 17 funds opened new Foghorn Therapeutics positions in Q4 2024 and 8 closed out, a net change of +9 holders.
- The largest Foghorn Therapeutics buyer in Q4 2024 was Point72 Asset Management, an estimated $1.71M added.
- The largest Foghorn Therapeutics seller in Q4 2024 was Fidelity Investments, an estimated $4.69M sold.
Based on aggregated 13F filings for Q4 2024.